From the gastrointestinal tract: at the beginning of treatment, transient abnormalities are possible: anorexia, stomach pain, nausea, vomiting, diarrhea, increased appetite, rarely constipation, pancreatitis up to severe lethal lesions.
From the side of the central nervous system: retardation, ataxia; tremor, changes in behavior, mood or mental state (depression, fatigue, hallucinations, aggressiveness, hyperactivity, psychosis, unusual arousal, motor anxiety or irritability), dizziness, drowsiness, headache, dysarthria, enuresis, stupor, impaired consciousness, coma .
From the sense organs: diplopia, nystagmus, flashing of "flies" before the eyes.
From the side of the liver: there may be a transient increase in hepatic enzyme activity observed during the first few months of treatment and often not showing any clinical symptoms (frequency about 40%).The risk of developing these side effects depends on the dose of the drug; when the dose decreases, these effects decrease or disappear. Very rarely there is a development of fulminant hepatitis with a lethal outcome, and it is not always possible to detect previous changes in liver function indices.
Allergic reactions: skin rash, alopecia, hives, angioedema, photosensitivity, malignant exudative erythema (Stevens-Johnson syndrome) are possible.
From the endocrine system: dysmenorrhea, secondary amenorrhea, breast enlargement, galactorrhea.
On the part of the organs of hematopoiesis and the system of hemostasis: anemia; thrombocytopenia, leukopenia, reduction of fibrinogen, platelet aggregation and clotting, accompanied by prolonged bleeding time, petechial hemorrhages, bruising, bruising, bleeding, etc.
From the side of metabolism: decrease or increase in body weight.
Laboratory indicators: hyperkreatininemia, hyperbilirubinemia, hyperammonemia, a slight increase in the activity of "hepatic" transaminases, lactate dehydrogenase (dose-dependent).
Other: peripheral edema.